‘Milestone’ Research Method Measures Gene Activity Across Whole Mice

Why It Matters

By enabling body‑wide molecular profiling, the method can accelerate drug safety assessment and uncover systemic disease pathways, reshaping preclinical research strategies.

Key Takeaways

• Whole-body spatial transcriptomics maps 5 million cells per slice
• 600,000 spots capture gene activity across 16 organ types
• Over 5,000 genes altered by bacterial toxin exposure
• Method reveals off‑target drug effects across organs
• Resolution limited to multi‑cell spots, not single‑cell

Pulse Analysis

The new platform merges cryomacrotome slicing with spatial transcriptomics, producing ultra‑thin, frozen sections of an entire mouse and overlaying them with millions of barcoded probes. Each of the 600,000 spots records RNA from a handful of cells, allowing researchers to reconstruct gene‑expression landscapes across the full 2 × 6 cm cross‑section. By adapting existing slide‑based technologies to a whole‑body scale, the team generated a high‑dimensional map that captured coordinated transcriptional responses in 16 organ systems and 37 sub‑regions, a feat previously limited to isolated tissues.

For pharmaceutical development, this holistic view could transform safety profiling. Drugs designed for hepatic targets can now be evaluated for unintended activity in the heart, spleen, or brain within a single experiment, reducing the need for multiple organ‑specific assays. Similarly, disease models—such as inflammatory responses to bacterial toxins—can be examined for systemic ripple effects, informing more precise therapeutic interventions. Evolutionary biologists also stand to benefit, as comparable whole‑body maps across species could illuminate conserved and divergent tissue‑level gene programs.

The technique’s primary limitation is its spot‑based resolution, which aggregates signals from several cells and may miss rare transcripts. Nevertheless, the trade‑off yields unprecedented breadth, and ongoing advances in probe density and computational deconvolution are expected to narrow the gap toward single‑cell fidelity. As the biotech sector embraces large‑scale spatial omics, this milestone positions spatial transcriptomics as a cornerstone of next‑generation drug discovery and systems biology, promising a surge of insights from whole‑organism molecular imaging.